FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises
Nearly 11 years ago, scientists programmed a pair of molecular scissors to make precise cuts in DNA. That first test tube experiment of CRISPR gene editing technology won its creators a Nobel Prize, ignited a gene editing revolution in life science labs, and kick-started a race to develop gene-altering medicines.
Now, the finish line is in sight. For the first time, a CRISPR therapy is up for FDA approval, Vertex and CRISPR Therapeutics announced Thursday evening.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.